Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice

Kuo Wei Hsueh, Tzyy Wen Chiou, Shu Fen Chiang, Toru Yamashita, Koji Abe, Cesar V. Borlongan, Paul R. Sanberg, Angelayu Hsuan Huang, Shinn Zong Lin, Horng Jyh Harn

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Amyotrophic lateral sclerosis (ALS) is a lethal degenerating disease, characterized by progressive muscular atrophy without any effective treatment. Here, we demonstrated the efficacy of abrograting autophagy in motor neurons (MN) by treatment with n-butylidenephthalide (n-BP) in ALS transgenic mice (SOD1G93A). Pre-symptomatic oral administration of 250 mg/kg/bid n-BP significantly prolonged the survival period (203.9 ± 18.3 days), improved motor function, and attenuated MN loss compared to vehicle control (126.4 ± 7.2 days). This prolonged survival of ALS mice is much more robust than that reported with riluzole (140 days), which is an approved clinical therapy for ALS. The therapeutic mechanism targeted by n-BP involved the autophagic pathway as evidenced by decreased LC3-II expression (a biomarker of autophagy), enhanced mTOR levels, and attenuated autophagic activity, altogether increasing MN survival in a dose-dependent manner. This result was also confirmed by double transgenic mice (SOD1G93A:LC3-GFP) which showed that oral administration of n-BP reduced GFP density and decreased caspase-3 expression. In addition, electron microscopy revealed that n-BP administration not only decreased autophagosome number but also reduced morphological dysfunction of mitochondria. In summary, these results indicate that down-regulation of autophagy activation via n-BP may pose as a therapeutic regimen for ALS and relevant neurodegenerative diseases.

Original languageEnglish
Pages (from-to)152-160
Number of pages9
JournalNeuropharmacology
Volume108
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Amyotrophic Lateral Sclerosis
Motor Neurons
Down-Regulation
Autophagy
Transgenic Mice
Oral Administration
Riluzole
Therapeutics
Spinal Muscular Atrophy
Caspase 3
Neurodegenerative Diseases
butylidenephthalide
Electron Microscopy
Mitochondria
Biomarkers

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice. / Hsueh, Kuo Wei; Chiou, Tzyy Wen; Chiang, Shu Fen; Yamashita, Toru; Abe, Koji; Borlongan, Cesar V.; Sanberg, Paul R.; Huang, Angelayu Hsuan; Lin, Shinn Zong; Harn, Horng Jyh.

In: Neuropharmacology, Vol. 108, 01.09.2016, p. 152-160.

Research output: Contribution to journalArticle

Hsueh, KW, Chiou, TW, Chiang, SF, Yamashita, T, Abe, K, Borlongan, CV, Sanberg, PR, Huang, AH, Lin, SZ & Harn, HJ 2016, 'Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice', Neuropharmacology, vol. 108, pp. 152-160. https://doi.org/10.1016/j.neuropharm.2016.03.035
Hsueh, Kuo Wei ; Chiou, Tzyy Wen ; Chiang, Shu Fen ; Yamashita, Toru ; Abe, Koji ; Borlongan, Cesar V. ; Sanberg, Paul R. ; Huang, Angelayu Hsuan ; Lin, Shinn Zong ; Harn, Horng Jyh. / Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice. In: Neuropharmacology. 2016 ; Vol. 108. pp. 152-160.
@article{4f4d8284e7754de09826beb7012b0743,
title = "Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice",
abstract = "Amyotrophic lateral sclerosis (ALS) is a lethal degenerating disease, characterized by progressive muscular atrophy without any effective treatment. Here, we demonstrated the efficacy of abrograting autophagy in motor neurons (MN) by treatment with n-butylidenephthalide (n-BP) in ALS transgenic mice (SOD1G93A). Pre-symptomatic oral administration of 250 mg/kg/bid n-BP significantly prolonged the survival period (203.9 ± 18.3 days), improved motor function, and attenuated MN loss compared to vehicle control (126.4 ± 7.2 days). This prolonged survival of ALS mice is much more robust than that reported with riluzole (140 days), which is an approved clinical therapy for ALS. The therapeutic mechanism targeted by n-BP involved the autophagic pathway as evidenced by decreased LC3-II expression (a biomarker of autophagy), enhanced mTOR levels, and attenuated autophagic activity, altogether increasing MN survival in a dose-dependent manner. This result was also confirmed by double transgenic mice (SOD1G93A:LC3-GFP) which showed that oral administration of n-BP reduced GFP density and decreased caspase-3 expression. In addition, electron microscopy revealed that n-BP administration not only decreased autophagosome number but also reduced morphological dysfunction of mitochondria. In summary, these results indicate that down-regulation of autophagy activation via n-BP may pose as a therapeutic regimen for ALS and relevant neurodegenerative diseases.",
author = "Hsueh, {Kuo Wei} and Chiou, {Tzyy Wen} and Chiang, {Shu Fen} and Toru Yamashita and Koji Abe and Borlongan, {Cesar V.} and Sanberg, {Paul R.} and Huang, {Angelayu Hsuan} and Lin, {Shinn Zong} and Harn, {Horng Jyh}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.neuropharm.2016.03.035",
language = "English",
volume = "108",
pages = "152--160",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice

AU - Hsueh, Kuo Wei

AU - Chiou, Tzyy Wen

AU - Chiang, Shu Fen

AU - Yamashita, Toru

AU - Abe, Koji

AU - Borlongan, Cesar V.

AU - Sanberg, Paul R.

AU - Huang, Angelayu Hsuan

AU - Lin, Shinn Zong

AU - Harn, Horng Jyh

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Amyotrophic lateral sclerosis (ALS) is a lethal degenerating disease, characterized by progressive muscular atrophy without any effective treatment. Here, we demonstrated the efficacy of abrograting autophagy in motor neurons (MN) by treatment with n-butylidenephthalide (n-BP) in ALS transgenic mice (SOD1G93A). Pre-symptomatic oral administration of 250 mg/kg/bid n-BP significantly prolonged the survival period (203.9 ± 18.3 days), improved motor function, and attenuated MN loss compared to vehicle control (126.4 ± 7.2 days). This prolonged survival of ALS mice is much more robust than that reported with riluzole (140 days), which is an approved clinical therapy for ALS. The therapeutic mechanism targeted by n-BP involved the autophagic pathway as evidenced by decreased LC3-II expression (a biomarker of autophagy), enhanced mTOR levels, and attenuated autophagic activity, altogether increasing MN survival in a dose-dependent manner. This result was also confirmed by double transgenic mice (SOD1G93A:LC3-GFP) which showed that oral administration of n-BP reduced GFP density and decreased caspase-3 expression. In addition, electron microscopy revealed that n-BP administration not only decreased autophagosome number but also reduced morphological dysfunction of mitochondria. In summary, these results indicate that down-regulation of autophagy activation via n-BP may pose as a therapeutic regimen for ALS and relevant neurodegenerative diseases.

AB - Amyotrophic lateral sclerosis (ALS) is a lethal degenerating disease, characterized by progressive muscular atrophy without any effective treatment. Here, we demonstrated the efficacy of abrograting autophagy in motor neurons (MN) by treatment with n-butylidenephthalide (n-BP) in ALS transgenic mice (SOD1G93A). Pre-symptomatic oral administration of 250 mg/kg/bid n-BP significantly prolonged the survival period (203.9 ± 18.3 days), improved motor function, and attenuated MN loss compared to vehicle control (126.4 ± 7.2 days). This prolonged survival of ALS mice is much more robust than that reported with riluzole (140 days), which is an approved clinical therapy for ALS. The therapeutic mechanism targeted by n-BP involved the autophagic pathway as evidenced by decreased LC3-II expression (a biomarker of autophagy), enhanced mTOR levels, and attenuated autophagic activity, altogether increasing MN survival in a dose-dependent manner. This result was also confirmed by double transgenic mice (SOD1G93A:LC3-GFP) which showed that oral administration of n-BP reduced GFP density and decreased caspase-3 expression. In addition, electron microscopy revealed that n-BP administration not only decreased autophagosome number but also reduced morphological dysfunction of mitochondria. In summary, these results indicate that down-regulation of autophagy activation via n-BP may pose as a therapeutic regimen for ALS and relevant neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=84969667346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969667346&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2016.03.035

DO - 10.1016/j.neuropharm.2016.03.035

M3 - Article

VL - 108

SP - 152

EP - 160

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -